News and Trends 17 Nov 2022 Ascletis announces IND approval for treatment of advanced solid tumors …dependent manner, with an EC50 of 2.86 nM. Maximal levels of IFNγ induced by ASC61-A were similar to that induced by Keytruda, a marketed PD-1 antibody. Compared with PD-1/PD-L1 antibody injections,… November 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 New drug boosts options for rheumatoid arthritis treatment …of the currently available therapeutic options. The new drug olokizumab is a humanized monoclonal antibody that directly targets the interleukin-6 cytokine. This is a messenger molecule that, like TNF, activates… August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Igyxos Biotherapeutics 2 Dec 2025 Rethinking infertility treatment: Treating couples, not just women …is a unique treatment for infertility in both its modality and mechanism of action. It is a first-in-class humanized monoclonal antibody (mAb) that potentiates the bioactivity of FSH to promote… December 2, 2025 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Acticor Biotech gets patent for cardiovascular emergency treatment product …to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke. Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major… June 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2023 Etana secures funding for oncology pipeline …recombinant humanized anti-VEGF monoclonal antibody drug for cancer patients in Indonesia. PT Etana Biotechnologies also produces erythropoietin (EPO) for dialysis treatment. The company plans to develop an adenovirus platform for… March 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2019 European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm …aim to stop relapses in the most common form of the condition, known as relapsing-remitting multiple sclerosis. The Danish antibody developer Genmab presented results from its drug ofatumumab, which is… September 17, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Jan 2025 Curing ALS? Sixteen companies developing new treatments in 2025 …novel antibody-based therapeutics for ALS. This partnership leverages Alchemab’s discovery platform to identify potential therapeutic antibodies from patients exhibiting slow ALS progression. While specific development stages of these candidates have… January 22, 2025 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 Biocytogen launches nanobody therapeutics project for 100 targets …therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC). After several years of work, Biocytogen successfully engineered the RenNano mouse from its fully human antibody… February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Apr 2025 Seven biotechs to watch in the hepatitis B space …its pipeline when it went public for $110.5 million in May 2021. Bluejay Therapeutics Therapeutic candidate: BJT-778 Technology: monoclonal antibody Recent funding: $182 million series C Another California-based biotech, Bluejay Therapeutics,… April 22, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Scancell looking to partner after positive COVID vaccine data …cell response. RBD neutralizing antibody titres against the Beta variant doubled in 44% of subjects and NCAP antibody titres doubled in 42% of participants. Scancell said of particular interest was… February 14, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2024 CureVac: From a failed drug to a €1.45 billion deal …trials began in mid-2020, with phase 1 and 2a trials showing that CVnCoV was generally well tolerated and induced strong antibody responses comparable to those seen in recovered COVID-19 patients…. August 1, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab …in Nature Cancer demonstrating the role of patient-derived organoids in the preclinical development and validation of a new bispecific antibody. This collaborative work by the European consortium (SuppresSTEM), coordinated by… July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email